Register of
Medicinal Products

Product class: Authorized package
Medicinal product class: For human use
Package code: 1533035
Name of medicinal product: CINRYZE
Active substances:
C1-inhibitor, plasma derived
Estonian, English, Latin
ATC code: B06AC01
Dosage form: powder and solvent for solution for injection
Route of administration: intravenous use
Strengh: 500RÜ
Amount in package: 2TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information: lahusti viaalis 5 ml
Indication: Treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.
Safety features: Yes
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Last imported to Estonia: June 30, 2022
: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Patients and healthcare professionals are asked to report any suspected adverse reactions to State Agency of Medicines.State Agency of Medicines
Marketing authorization holder: Takeda Manufacturing Austria AG 
Marketing authorization number: EU/1/11/688 
Marketing authorization issued on: June 15, 2011 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Centralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: August 17, 2022
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere